Irbesartán Cinfa

Irbesartan, the active ingredient in Irbesartán Cinfa, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and diabetic nephropathy in adult patients. GNH USA supplies Irbesartán Cinfa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker used to manage conditions linked to the renin‑angiotensin system.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes.

Common side effects are generally mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Upper respiratory tract infection - Diarrhoea - Hyperkalemia (mild)

Serious or Rare Side Effects: - Angioedema - Acute renal failure - Severe hyperkalemia - Hepatic injury - Neutropenia or agranulocytosis - Anaphylactic reaction

Before initiating therapy, clinicians should assess patient‑specific factors and monitor relevant parameters.

Monitor blood pressure regularly: ensure therapeutic response and avoid hypotension. Check renal function: baseline and periodic serum creatinine measurements are recommended. Assess serum potassium: avoid hyperkalemia, especially when combined with potassium‑sparing agents. Avoid use in pregnancy: teratogenic risk is unknown; discontinue if pregnancy is detected. Use caution in hepatic impairment: dose adjustment may be required. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Dual therapy with ACE inhibitors or other ARBs: heightened risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause severe hyperkalemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose titration. - Lithium: may increase lithium levels, necessitating serum monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive efficacy and affect renal function. - CYP2C9 inhibitors (e.g., fluconazole): may modestly increase irbesartan plasma concentrations.